NKNiloofar Khosravi

Niloofar Khosravi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Niloofar Khosravi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aspirin limits platelet TXA2-mediated suppression of T-cell immunity to prevent cancer metastasis

    by Kianoush Saberi, Atieh Okhli, Khorsid Rigi, Seyed Amir Banikarim, Sara Teihou Jorshari, Niloofar Khosravi, Zahed Karimi, Anna Ghorbani Doshantapeh, Shahnaz Sharifi

    Aspirin, a widely used non-steroidal anti-inflammatory drug, has shown promise in cancer prevention and reducing metastatic progression. This medication limits platelet thromboxane A2 (TXA2)-mediated suppression of T-cell immunity, thereby preventing cancer metastasis. Platelets, beyond their role in hemostasis, actively contribute to tumor progression and metastasis by various mechanisms, including shielding circulating tumor cells from immune surveillance and promoting their extravasation. One critical pathway involves platelet-derived TXA2, a potent lipid mediator that can directly suppress anti-tumor T-cell responses. TXA2 promotes immune evasion by inhibiting T-cell activation and proliferation, thus hindering the body’s ability to effectively eliminate cancerous cells. Aspirin’s well-known inhibitory effect on cyclooxygenase-1 (COX-1) is key here, as COX-1 is responsible for TXA2 synthesis in platelets. By irreversibly acetylating COX-1, aspirin effectively reduces TXA2 production. Then, the reduction in platelet TXA2 alleviates its immunosuppressive effects on T-cells, thereby restoring and enhancing anti-tumor immunity. The enhanced T-cell activity can then more effectively target and destroy circulating tumor cells, finally limiting the formation of secondary tumors and preventing metastasis.


  • Relationship between neutrophil percentage to albumin ratio and kidney disease: systematic review and meta-analysis

    by Kianoush Saberi, Abnoos Mokhtariardekani, Shahnaz Sharifi, Maede Safari, Maryam Marahemi, Niloofar Khosravi, Roozbeh Roohinezhad, Hamid Rastad, Mahdi Razmi

    Introduction: The neutrophil percentage-to-albumin ratio (NPAR) has emerged as a valuable biomarker for the detection and assessment of inflammatory conditions. Given the prominent role of inflammation in the pathophysiology of kidney disorders, the present study aimed to examine the association between NPAR and the risk of developing kidney disease. Materials and Methods: This study was conducted as a systematic review and meta‑analysis, designed in accordance with the PRISMA guidelines. In line with this framework, the Cochrane, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, were systematically searched up to December 19, 2025. All statistical analyses were performed using STATA version 14. Results: Elevated NPAR was significantly associated with an increased risk of kidney disease in the overall population (OR = 1.62, 95% CI: 1.37–1.91), as well as among men (OR = 1.31, 95% CI: 1.15–1.50), women (OR = 1.30, 95% CI: 1.14–1.48), and individuals younger than 60 years (OR = 1.71, 95% CI: 1.42–2.06). Participants in the highest NPAR quartile demonstrated a markedly greater risk of kidney disease compared with those in the first quartile (OR = 2.04, 95% CI: 1.46–2.84), the third quartile (OR = 1.40, 95% CI: 1.13–1.72), and the second quartile (OR = 1.19, 95% CI: 1.07–1.31). Similarly, individuals in the third NPAR tertile exhibited a substantially higher risk relative to the first tertile (OR = 4.40, 95% CI: 2.26–8.58) and the second tertile (OR = 2.63, 95% CI: 1.34–5.19). Furthermore, elevated NPAR was identified as a significant risk factor for both chronic kidney disease (CKD) (OR = 1.46, 95% CI: 1.17–1.82) and diabetic kidney disease (OR = 1.86, 95% CI: 1.43–2.43). Conclusion: Elevated NPAR was associated with a higher likelihood of developing kidney disease, and this risk increased progressively with rising NPAR levels. Men demonstrated a slightly greater vulnerability compared with women, and a younger age (<60 years) further amplified this association. Additionally, individuals with higher NPAR values exhibited a greater propensity for developing diabetic kidney disease than CKD. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251273807) and Research Registry (UIN: reviewregistry2069) websites.

  • Open Access

    Relationship between neutrophil percentage to albumin ratio and cardiovascular disease mortality in chronic kidney disease patients; a systematic review and meta-analysis

    by Mohammad Rostamzadeh, Yaser Abolhasani, Amir Heidari, Abdolmohammad Ranjbar, Ali Emadzadeh, Maede Safari, Niloofar Khosravi, Samaneh Zandifar, Roozbeh Roohinezhad, Mohamadnavid Vanda, et al.

    Introduction: Chronic inflammation plays a significant role in cardiovascular disease (CVD)–related mortality among patients with chronic kidney disease (CKD). The neutrophil‑to‑albumin percentage ratio (NPAR) has emerged as an indicator of an individual’s inflammatory status. This study aimed to investigate the association between elevated NPAR and the risk of CVD mortality in patients with CKD. Materials and Methods: The study was conducted in accordance with the PRISMA reporting guidelines. Comprehensive searches were performed across the Cochrane Library, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to 30 January 2026. All statistical analyses were carried out using STATA version 14. Results: Compared with lower NPAR values, elevated NPAR was associated with a higher risk of cardiovascular mortality (OR = 1.54; 95% CI: 1.33–1.78) and all‑cause mortality (OR = 1.62; 95% CI: 1.40–1.89) in patients with CKD. In addition, higher NPAR increased the risk of CVD‑related death among patients undergoing hemodialysis (OR = 1.66; 95% CI: 1.29–2.15) and peritoneal dialysis (OR = 1.56; 95% CI: 1.25–1.94). Furthermore, the third quartile of NPAR (OR = 1.44; 95% CI: 1.16–1.78), the fourth quartile (OR = 1.92; 95% CI: 1.61–2.30), the second tertile (OR = 1.38; 95% CI: 1.07–1.80), and the third tertile (OR = 1.97; 95% CI: 1.61–2.41) were all associated with increased CVD mortality compared with the lowest category. Elevated NPAR also increased the risk of CVD‑related mortality in both men (OR = 1.23; 95% CI: 1.04–1.45) and women (OR = 1.16; 95% CI: 1.08–1.24) with CKD. Conclusion: Higher NPAR levels were associated with an increased likelihood of cardiovascular and all‑cause mortality among individuals with CKD. As NPAR values rose, the risk of CVD‑related death increased correspondingly when compared with lower levels. In addition, cardiovascular mortality risk was greater in men than in women, and higher among patients receiving hemodialysis than those undergoing peritoneal dialysis. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261304086) and Research Registry (UIN: reviewregistry2082) websites.

  • Comparative efficacy of dural puncture epidural, epidural analgesia, and combined spinal‐epidural techniques in obstetrics: Quality of analgesia, side effects, and labor analgesia phase outcomes: Narrative review

    by Niloofar Khosravi, Reza Farahmand Rad, Salume Sehat Kashani

    Epidural analgesia has become a cornerstone in pain management during labor, offering effective relief while allowing the mother to remain conscious and actively participate in the birthing process. In obstetrics practice, the use of epidural techniques has evolved to enhance maternal comfort, improve labor experience, and facilitate smoother delivery outcomes. Various methods of epidural analgesia have been developed, each with distinct procedural approaches, benefits, and potential risks. Understanding these different techniques is essential for midwives and obstetric teams to tailor pain management strategies to individual patient needs. Pain during labor is a significant concern for many women, affecting their physical comfort, emotional well‐being, and overall childbirth experience. Unmanaged or inadequately controlled pain can lead to increased stress, fatigue, and even adverse physiological responses that can complicate labor progress. Effective pain management not only enhances maternal satisfaction but also contributes to better labor outcomes and reduces the likelihood of interventions such as cesarean sections. Consequently, exploring optimal methods of analgesia, particularly epidural techniques, remains a priority in obstetrics and obstetric care. This review aims to systematically compare the various epidural analgesia methods used in obstetric practice, focusing on their efficacy, safety profiles, and impact on labor progression. By investigating different techniques such as dural puncture epidural, standard epidural, and combined spinal–epidural approaches, the research seeks to identify the most effective and safest options for pain relief during labor. The findings intend to inform clinical decision‐making, optimize patient outcomes, and guide best practices in the administration of epidural analgesia for painless delivery.

  • Open Access

    A Comparative Study of the Effect of Labetalol and Remifentanil on Pain Control After Bariatric Surgery

    by Masood Mohseni, Reza Farahmand Rad, Ali Akbar Jafarian, Mojtaba Rostami, Niloofar Khosravi

    Background: Finding the optimal combination of anesthetics to maintain hemodynamic stability during surgery can be challenging. Traditionally, strong opioid analgesics such as fentanyl and its newer analogs have been used. However, the use of narcotics is associated with certain side effects. Objectives: This study compares the effects of labetalol and remifentanil in pain control after bariatric surgery in Hazrat Rasool Akram Hospital. Methods: This randomized, double-blind clinical trial was conducted on 48 laparoscopic bariatric surgery patients. The participants were randomly divided into two groups receiving remifentanil or labetalol. Postoperative pain was measured in the recovery unit using the numerical rating scale (NRS). This score was recorded upon entering recovery, and 30 minutes, 60 minutes, and 120 minutes after surgery for each patient. Also, the duration of anesthesia, the duration of the operation, the recovery time, the dose of the administered opioids, the volume of intravenous fluids, and the dose of administered propofol were recorded for each patient. Nausea and vomiting after the operation were also recorded as outcomes. Results: There were no significant differences between the two groups regarding the mean duration of surgery and anesthesia, dose of the administered anesthetics, recovery period, nausea and vomiting, and the dose of analgesics after the operation. The mean pain intensity during the given period and also the trend of pain intensity changes between the two groups demonstrated no statistically significant differences (P = 0.112). During the operation, 9 subjects (37.5%) in the labetalol group and 16 (66.7%) in the remifentanil group needed more analgesics (rescue drug); in this regard, a significant difference was observed between the two groups (P = 0.043). Conclusions: Based on the study’s findings, there were no significant differences between labetalol and remifentanil in post and perioperative pain control. However, rescue drugs needed to maintain hemodynamic stability during laparoscopic surgery were significantly lower in patients who received labetalol than remifentanil. Postoperative complications were also comparable between labetalol and remifentanil.


  • Open Access

    Comparison of Perioperative Pregabalin and Duloxetine for Pain Management After Total Knee Arthroplasty: A Double-Blind Clinical Trial

    by Farnad Imani, Azadeh Emami, Mahzad Alimian, Nasim Nikoubakht, Niloofar Khosravi, Mehdi Rajabi, Arthur Christopher Hertling

    Background: Chronic residual pain after total knee arthroplasty (TKA) is one of the challenges of postoperative pain management. Duloxetine, by controlling neuropathic pain, and pregabalin, by affecting nociceptors, can effectively manage postoperative pain. Objectives: This study aimed to compare the effect of perioperative oral duloxetine and pregabalin in pain management after knee arthroplasty. Methods: In this clinical trial, 60 patients scheduled for TKA under spinal anesthesia were randomly assigned to one of three groups A (pregabalin 75 mg), B (duloxetine 30 mg), and C (placebo). Drugs were administered 90 minutes before, 12, and 24 hours after surgery. The visual analog scale (VAS) score for pain, the first analgesic request time, postoperative analgesic consumption (i.v. paracetamol), and WOMAC score six months after surgery were recorded. Results: The VAS score and analgesic consumption 48 hours after TKA in groups A and B significantly decreased compared to the placebo (P < 0.05). The first analgesic request time was longer in groups A and B than in group C (P < 0.05). While the differences were statistically significant, they are most likely not clinically significant. The WOMAC score before and six months after arthroplasty did not differ between the groups (P > 0.05). Conclusions: Perioperative oral pregabalin and duloxetine similarly reduce pain and the need for analgesic consumption within 48 hours after TKA but do not affect knee mobility status.